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Chronic kidney disease is a major healthcare problem worldwide and its cost is 
becoming no longer affordable. Indeed, restoring damaged renal structures or 
building a new kidney represent an ambitious and ideal alternative to renal 
replacement therapy. Streams of research have explored the possible application 
of pluripotent SCs (embryonic SCs and induced pluripotent SCs) in different 
strategies aimed at regenerate functioning nephrons and at understanding the 
mechanisms of kidney regeneration. 
Areas covered 
 
In this review, we will focus on the main potential applications of human 
pluripotent SCs to kidney regeneration, including those leading to rebuilding 
new kidneys or part of them (organoids, scaffolds, biological microdevices) as 
well as those aimed at understanding the pathophysiological mechanisms of 
renal disease and regenerative processes (modeling of kidney disease, genome 
editing). Moreover, we will discuss the role of endogenous renal progenitors 
cells in order to understand and promote kidney regeneration, as an attractive 
alternative to pluripotent SCs. 
Expert opinion 
 
Opportunities and pitfalls of all these strategies will be underlined, finally 
leading to the conclusion that a deeper knowledge of the biology of 
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• Human pluripotent stem cells (SCs) include embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs). These cells can provide useful tools 
either to therapeutic purposes either to investigate disease pathophysiology 
and mechanisms, including renal diseases and kidney regeneration. 
• ESCs have the advantage to be relatively quick to obtain and to be not 
anymore subject to licensing/royalty to be paid. Anyway, some major 
concerns, such as ethical issues, the high risk to degenerate in neoplasms and 
immunocompatibility, still remain open 
• iPSCs have the great advantage of harboring the same genetic background 
of the individual they are derived, thus representing an ideal tool to study 
the effects of genetic variants in the pathogenesis of diseases. The main risks 
connected with the use of iPSCs are represented by tumorigenicity and 
immunogenicity, the presence of an epigenetic memory, technical and 
economical problems related to their long turnaround time and the presence 
of loyalties. 
• Human pluripotent SCs has two main fields of application in kidney 
regeneration: they can be used to build “a new kidney” or part of it by the 
mean of studies on organoids, scaffolds, organ-on-a-chip and blastocyst 
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complementation, or they can be used to investigate the mechanisms of 
kidney regeneration trough disease modeling and gene editing. 
• Renal progenitor cells represent an attractive alternative either to study or to 
modulate kidney regeneration, providing important advantages in the field. 
• A deeper knowledge of the biology of pluripotent SCs is mandatory, in order 





Chronic kidney disease (CKD) is a major healthcare issue worldwide. Recent 
studies report that at least 10% of the adult population in western countries 
suffers from a variable level of CKD [1-4], probably representing only the “tip of 
the iceberg” of one of the wounds of the 21st Century. Irrespective of the nature 
of the disease that leads to the loss of kidney function, CKD can progress toward 
end-stage renal disease (ESRD), requiring dialysis or kidney transplantation to 
allow patients to survive. Considering that kidney diseases are frequently 
clinically silent and CKD is largely undiagnosed, it is easy to understand how 
this issue could potentially assume catastrophic proportions. Moreover, the 
social, economic and healthcare burden to sustain long-term renal replacement 
therapies (RRT) is tremendous and probably no longer affordable worldwide [4, 
5]. 
It is in this context that kidney regeneration has received an impressive push 
forward. Indeed, restoring damaged renal structures or building a new kidney 
represent an ambitious and ideal alternative to RRT. Adult human kidney has a 
limited number of nephrons, determined during embryonic development by a 
multitude of genetic and environmental factors, that could not be modified after 
the 36th week of gestation [6-9]. This is commonly believed to be due to  the 
exhaustion of a population of nephron progenitor cells [6, 8, 9]. This inherent 
incapability of total kidney regeneration in humans poses a detrimental limit to 
the opportunity of regenerative medicine in nephrology. Notwithstanding this, 
streams of research have tried to overcome this border 
6	 
and some ways toward the application of strategies for kidney regeneration 










Irrespective of the species, pluripotent SCs are cultured cells sharing with the 
blastocyst-stage embryo the capability to generate an entire body [10]. From a 
functional point of view, they possess two principal properties: a high 
proliferative ability and a broad differentiation capacity. The first one, also 
known as self-renewal, refers to the ability to extensively replicate without 
undergoing differentiation or senescence, while the second consists in the 
property of differentiate into more than one mature somatic cell type from each 
of the three embryonic germ layers (namely, ectoderm, mesoderm and 
endoderm) [7, 11-13]. In mammals, including humans, pluripotent SCs 
progressively exhaust during embryonic development, probably giving rise to 
tissue-restricted stem/progenitor cells, usually referred to as committed 
stem/progenitors cells. The capability to persist after fetal life depends on the 
functional features of the cell population and on the regenerative potential of 
the organ they belong with, that could allow stem cell niches to build and to 
maintain their function. 
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Based on their functional properties, pluripotent SCs can be long-term cultured 
in vitro. When exposed to determined culture conditions (e.g deprivation of 
growth factors that maintain pluripotency), pluripotent SCs undergo stochastic 
differentiation. Consequently, they give rise to embryoid bodies in vitro while 
by implantation into an immunodeficient animal host, these cells generate 
teratomas [7, 11, 14]. Both embryoid bodies and teratomas contain cell types 
owing to the three embryonic germ layers, thus proving the pluripotency of the 
cell they originate from. In addition, direct differentiation by exposing 
pluripotent SCs to growth or inhibitors factors that have been demonstrated to 
specifically regulate progressive steps of embryonic development is an 
alternative option to obtain the mature cell type of interest, in particular of 
kidney cells [7, 14, 15]. 
Human pluripotent SCs include embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs). Indeed, the properties of these two cell 
populations as pluripotent SCs have been unequivocally demonstrated. These 
cells can provide useful tools either to therapeutic purposes either to investigate 
disease pathophysiology and mechanisms. 
 
 
2.1 Embryonic stem cells 
 
ESCs represent the culprit of pluripotent SCs. They are primary cultures of 
human embryonic cells from the inner cell mass of the blastocyst, about 5 after 
fertilization [16]. They are separated and grown in culture after derivation 
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from embryos [11] and can be induced to differentiate into a broad range of cell 
types [17]. 
They surely provide a hopeful strategy for kidney regenerative therapies (Figure 
1). They are capable of differentiation into different kidney mature cell types. 
The first report of ESCs use to obtain renal cells was provided in Xaenopus leavis, 
by exposing the ectoderm to mesoderm-inducing factors (e.g. retinoic acid, 
activin A) [18-20]. This strategy allowed authors to obtain cells of the 
pronephros, including glomerular and tubular cells [18, 21, 22]. Similar studies 
were subsequently performed in mammalian metanephric kidney, including the 
human one, with success in obtaining renal progenitor cells from embryonic 
bodies [7, 23-26]. Indeed, most protocols of human ESCs differentiation to 
kidney cells have been translated from studies in mice, including strategies for 
differentiation of ESCs in nephron precursor population and even direct 
differentiation in more mature kidney cells, bypassing nephron precursors [23, 
27-33]. These studies allowed the authors to generate populations of podocyte- 
and renal tubular epithelial-like cells, whose phenotypic and functional 
properties anyway still remain to be clearly stated [7, 34, 35]. 
ESCs can be relatively quickly obtained (around 20 weeks) and are not anymore 
subject to licensing/royalty to be paid. Therefore, they represent a relatively 
easy-to-obtain cellular tools. Anyway, some major concerns still remain open 
talking about ESCs. Firstly, ESCs-based methods are inherently burden with 
ethical issues that have significantly limited their use, at least in some countries. 
Secondly, cells and tissues derived from ESCs are at high risk 
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to degenerate in neoplasms, especially teratomas [36]. Lastly, ESCs-derived 
differentiated cells are allogeneic in nature and they inevitably suffer from all 
the issues related to allografts and immunocompatibility (acute and chronic 
rejection, graft versus host disease, although the latest has been reported only in 
case of ESCs transplantation for bone marrow regeneration). 
 
 
2.2 Induced pluripotent stem cells 
 
iPSCs are somatic cells reprogrammed to acquire an ESC-like functional status 
[10]. iPSCs technology was first described in 2006 [37]. Briefly, somatic cells are 
transiently induced to overexpress embryonic transcription factors (OCT4, 
SOX2, KLF4, c-MYC in the initial work) that lead the cells to acquire a 
phenotypic and functional status similar to that of ESCs. 
iPSCs can be obtained by vector integration methods (e.g. retroviral vectors, 
lentiviral transgene integration) or integration-free methods (e.g. plasmids, 
Sendai virus, synthetized RNAs, proteins) that are less likely to persist after 
reprogramming [37-39]. iPSCs can be classified into primed and naive. Naive 
iPSCs model the inner cell mass of the pre-implantation blastocyst, whereas 
primed iPSCs resemble cells derived from post-implantation epiblasts. In 
general, naive iPSCs are easier to maintain and differentiate, but need to be 
obtained using chemically defined conditions. The difference between naïve and 
primed iPSCs, as well as their species of origin, could potentially influence the 
results of the studies performed and pose important challenge for their clinical 
use. 
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Although the efficiency of the reprogramming is low, iPSCs can be extensively 
expanded in culture, giving rise to various types of cells and tissues [40]. Like 
ESCs, iPSCs can generate derivatives of all the three germ layers after 
introduction into pre-implantation embryos. Following in vitro differentiation, 
iPSCs are able to generate cells that resemble renal progenitors and their 
progeny, such as podocytes and tubular epithelial cells (Figure 1) [34, 41-44]. 
iPSCs have the great advantage of harboring the same genetic background of 
the individual they are derived. As a natural consequence, they represent an 
ideal tool to study the effects of genetic variants in the pathogenesis of diseases 
[14] 
A major concern of iPSCs is the presence of an epigenetic memory, that is to  say 
a series of methylation/demethylation sites that are typical of the specific 
differentiated cell type and of the tissue/organ of origin. This feature could affect 
not only the ability of iPSCs-derived mature cells to reliably recapitulate the 
disease pathophysiology, but could also affect the differentiation capability, 
since it has been demonstrated that iPSCs preferentially differentiate back to the 
cell type of origin [45, 46]. This last issue may be probably at least in part 
overcome by a better knowledge of the molecular and genetic networks 
regulating the differentiation process from iPSCs and tissue specific  progenitors 
or mature cells. Moreover, it has been demonstrated that reprogrammed cells 
(iPSCs) differ from pluripotent SCs in the activation/inactivation of genetic loci 
previously thought to be highly stable. However, a great advantage in using 
iPSCs for understanding kidney regeneration could derive from generating 
them from kidney cells. Indeed, 
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iPSCs have been generated from cells of renal origin (mesangial, tubular 
epithelial cells, urine-derived renal epithelial cells) [34, 47-50], providing 
indisputable advantages for cell therapy and kidney regeneration. Indeed, 
kidney-derived iPSCs would retain not only the genetic background but also the 
renal peculiar epigenetic memory of the cell of origin. 
The main risks connected with the use of iPSCs are represented by the 
accumulation of somatic mutations that can result in tumorigenicity and 
immunogenicity. With regard to malignant transformations, some studies 
reported critical activation of oncogenes in iPSCs [36]. However, since cellular 
reprogramming is clonal in nature, it seems plausible to attribute the events of 
malignant transformation to genetic alterations that occur at low frequency in 
the starting population and that are inherent to it [39]. On the other hand, 
patient-derived iPSCs are not immunogenic in nature, but the accumulation of 
genetic mutation must be considered as a potentially confounding event with 
regard to immune tolerance [10, 39]. 
iPSCs pose technical and economical problems, since the turnaround time to 
obtain cultures is about one year per patient and the technology is protected by 
patent and its use requires the payment of loyalties, at least for commercial 
strategy[10]. This issue could at least in part be overcome by the building of 
banks of allogenic iPSCs that can provide clinical grade iPSCs within shorter 
time. On the other hand, since iPSCs are derived from adult individuals, the 




3. Exploring kidney regeneration: potential applications of human 
pluripotent stem cells 
 
 
As already mentioned, the adult human kidney is not able to generate new 
nephrons. As a consequence, pluripotent SCs have long been considered as the 
only cultivable cells capable of neo-nephrogenesis. Therefore, they represent the 
most studied tool in kidney regenerative medicine (Figure 1). 
Since the first description of cellular reprogramming and iPSCs technology 
development, questions about the differences existing among iPSCs and ESCs 
arose. Indeed, these two cell types differ in gene expression profiles, DNA 
methylation and pluripotent potential (i.e. differentiation ability), as assessed by 
different groups by microarrays studies, targeted bisulfite sequencing and 
assays of differentiation efficacy, respectively [17, 39]. Notwithstanding this, it 
is plausible that these differences are shades not very easy to assess and that 
iPSCs and ESCs have at least partially overlapping phenotypes, depending on 
the source of cells, the laboratory conditions used to obtain the cultures and even 
stochastic events, including genetic imprinting. Indeed, ECSs and iPSCs show 
exceptional similarities that could maybe be explained considering that are both 
obtained by laboratory manipulation [39, 51-53]. Therefore, the selection of ESCs 
or iPSCs clones suitable for medical application appears to be critical. With 
regard to kidney regeneration, pluripotent SCs must differentiate into kidney 
rather than other mature cells, be able to reproduce the spatial and 
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anatomical complexity of the organ, and then induced to acquire functionality 
[54]. Indeed, two major obstacles reside in kidney regeneration by human 
pluripotent SCs: first, the kidney contains a multitude of different cell types that 
has to be someway reconstructed and second, the organ begin to develop late in 
embryonic development, that is to say far away from the state of pluripotency 
[54]. 
Notwithstanding this, attempts to pave the way for pluripotent SCs to regenerate 
the kidney have been made. Indeed, recent advances in the SCs field, together 
with a great push of nanotechnologies, have enabled the in vitro generation of 
complex structures resembling whole kidneys, termed organoids, or part of 
them, like scaffolds and engineered glomerular filtration barriers. Besides this, 
the identification of endogenous repair and regeneration  strategies in injured 
kidney is another option that has to be taken into consideration in order to find 











The term “organoids” refer to suspensions of human pluripotent SCs that self 
organize in culture to form small organs and tissue arrangements [55-57]. 
Therefore, a kidney organoid is a miniaturized and simplified version of a 
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kidney produced in vitro, that shows a realistic renal microanatomy. The 
methodological and conceptual advance concerning organoids prompted 
researchers to use them not only for classical developmental experiments but 
also for regeneration studies. 
The first attempts to create kidney organoids for studying regeneration, 
however, obtained avascular fetal-like kidney tissues [55]. This obstacle was 
successfully overcome by using a dissociation/reaggregation method of mouse 
kidney cells that showed to be able to integrate into living recipients, to generate 
vascularized glomeruli and to perform nephron-specific functions [58]. The 
same authors then used this strategy to create chimeric kidney organoids from 
mixed suspension of murine embryonic kidney cells and human amniotic fluid 
SCs [59]. The ability to generate vascularized nephrons from single-cell 
suspensions marked a step forward on the way of replacing renal function by 
tissue-engineered kidneys. 
Important advances toward the generation of patient-specific organoids as tools 
for studying human kidney development, modeling disease, developing new 
drugs and evaluating novel regenerative strategies derived from the 
development of efficient protocols for the differentiation of human pluripotent 
SCs into kidney organoids. Indeed, when induced to differentiate in renal 
epithelial cells, human pluripotent SCs spontaneously organize into structures 
resembling different segment of the nephron, from glomeruli to collecting ducts 
[6, 42, 60, 61]. In particular, the exposure of iPSCs to different levels of Wnt 
agonist allowed authors to obtain pluripotent SCs of the metanephric 
mesenchyme and of the ureteric bud, giving rise to nephron structures that 
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recapitulate the most important developmental steps of the embryonic kidney 
[60]. These structures showed functional properties such as a spatial and 
temporal pattern of expression of markers specific of different segments of the 
nephron [60]. Almost simultaneously, kidney organoids have been created from 
human ESCs [61]. Human pluripotent SCs-derived organoids contain all the 
components of the fetal human kidney (nephrons, collecting ducts, endothelial 
cells, interstitium) [60, 61]. 
From a conceptual point of view, kidney organoids have two main principal 
functions concerning regenerative nephrology: to establish the similarity 
between human fetal kidney cells and the corresponding cells contained  within 
the organoids by the mean of morphological analysis and gene expression 
profile assays; to detect protocols for obtaining the differentiation  of cells 
present within the organoids into the specific renal cell lineages of interest [62]. 
The development of these protocols paved the way for the possibility of patient-
specific disease modeling and drug screening, at a further level than the cellular 
one, as well as for the replacement of renal tissue by bioengineering approaches. 
However, organoids are not a kidney. The complex large-scale organization of 
the organ, that is crucial for some of its functional properties, cannot be fully 
reproduced, making these structures far away to be considered as kidney 
replacing. Anyway, these organoids can be suitable for other medical purposes, 




Pluripotent SCs-derived organoids have provided interesting information about 
the capability of self-organization in similar-kidney structures. Notwithstanding 
this, this strategy could be inefficient in generating a sufficient number of cells 
for kidney regeneration purposes. Therefore, alternative solutions have been set 
up. In this view, “re-cellularization” of biologic or artificial scaffolds with 
appropriate combinations of specific renal cell types is an attractive hypothesis. 
These cells can be either isolated from pluripotent SCs-derived organoids, that 
are separated and expanded in culture, or differentiated in vitro from their 
specific tissue/cell of origin [62, 63]. Scaffolds can be made of purified silk, 3D-
printed polymer arrays, decellularized kidneys and extracellular matrix [63]. 
Independently on  the kind of scaffold, this approach requires the appropriate 
set-up of vascular structures (here including the correct development and 
localization of endothelial, smooth muscle and pericytes cells, as well as 
interstitial cells) to allow the scaffolds to be served by blood flow and the 
structures to be consequently functional [64, 65]. Finally, these newly generated 
structures should be communicate with collecting ducts to allow the urine 
stream to flow and kidney to fulfill all its functions [66]. The ultimate goal is to 
obtain synthetic kidneys that can be transplanted to a host [62]. 
 
 
3.1.3 Engineered glomerular filtration barrier and renal tubules 
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The glomerular filtration barrier (GFB) is a highly specialized structure 
interfacing with blood and responsible for its filtration. The integrity of the GFB 
is guaranteed by a correct anatomical and functional organization among its 
three principal constituents: the glomerular endothelial cell, the basement 
membrane, and the podocyte. Since many kidney disorders determine the loss 
of the GBF integrity, rebuilding a functioning GFB is a goal of regenerative 
medicine and represents another strategy for modeling kidney diseases [67]. 
The podocyte is a post-mitotic cell incapable of proliferation and cell division 
[68, 69]. It has been demonstrated that podocytes can be replaced by a progenitor 
cell, localized within the Bowman’s capsule, although this regeneration is 
limited [68-71]. The possibility to obtain a fully differentiated podocytes is 
therefore essential for modeling the GFB and studying kidney disorders and 
regeneration. In a recent study, iPSC-derived podocytes were put in the context 
of an engineered GFB that recapitulates the properties of the human glomerular 
capillary wall, to which mechanical forces resembling pulsatile blood flow were 
applied [72]. Human iPSCs-derived podocytes produced proteins of the 
glomerular basement membrane and showed foot processes that confer the 
permselectivity typical of the “native” GFB. By inducing podocytes damage, the 
authors recapitulated the morphological and phenotypic features of focal 
segmental glomerulosclerosis [72]. This strategy could be used for the modeling 
of many others kidney disorders, with particular attention to podocytopathies 
(genetic, toxic, infectious), adding to the cellular and molecular level the 
complexity of the GFB [67]. 
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In parallel to the development of artificial GFB, a significant number of studies 
reported on the generation of devices mimicking the structure of kidney tubules. 
Many studies used artificial microchip coated with primary lines of human 
tubular epithelial cells [73-78]. Upon the exposure to microfluidic shear stress, 
bioartificial renal tubules showed to recapitulate some of the main phenotypic 
and functional features of renal tubules, such as solute reabsorption and 
secretion and cellular polarization. These first studies introduced a new tool for 
exploring kidney regeneration, with particular regard to the tubular 
compartment. Indeed, it is plausible to hypothesize that artificial microdevices 
could be coated with patient-derived  human pluripotent SCs, thus allowing 
tubular diseases (like acute kidney injury, AKI) to be reliably recapitulated and 
drugs efficacy and nephrotoxicity to be tested in a personalized manner. 
 
 
3.1.4 Blastocyst complementation 
 
The generation of transplantable kidneys is among the ultimate goals of 
regenerative nephrology due to a shortage of donor organs, that represents a 
critical obstacle to the expansion of transplantation programs. Notwithstanding 
this, the complex 3D cellular and tissue interactions required for organogenesis 
are quite difficult to recapitulate in vitro. Blastocyst complementation is a 
method used to overcome these obstacles. Briefly, it consists in generating 
organs in vivo by injecting pluripotent SCs (either ESCs or iPSCs) into blastocyst-
stage embryos (mainly, but not exclusively, rodents). 
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This finally leads to the generation of chimeric embryos in which pluripotent 
SCs contribute to the generation of host tissues and organs [79]. Interspecies 
blastocyst complementation is a variation of the classical technique in which the 
recipient host is genetically manipulated to carry DNA mutations that prevent 
the development of a target organ [80]. Ideally, the injection of donor- derived 
pluripotent SCs would developmentally compensate for the defect  and form 
the missing organ. This strategy had been initially used for the reconstitution of 
bone marrow but was subsequently applied to the generation of entire organs 
(e.g. pancreas, heart, eye) [81]. The resulting organs are composed almost 
entirely of cells derived from donor, even if the blastocyst complementation 
involves different species. 
To the aim of kidney organogenesis, this technique has been used in few works 
that arose the possibility of widening the opportunities of kidney regeneration. 
In the very first experiment, wild-type mouse pluripotent SCs were injected into 
Sall1 knockout mouse blastocysts in which kidneys did not developed because 
of the genetic defect [79]. This led to the generation of kidneys entirely formed 
by the injected mouse-derived cells, except for structures not under the influence 
of Sall1 expression (such as collecting ducts and microvasculature), thus 
rescuing bilateral renal agenesis [79]. Unfortunately, the resulting chimeric 
animals did not survive until adulthood for reasons that are not completely clear 
[79]. Following the first experiments performed in rodents, the research shifted 
to generate chimeric animals between human pluripotent SCs and larger 
animals (e.g. pigs), in order to obtain organs sized as closer as possible to that of 
humans. To this aim, the potential of human pluripotent SCs 
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to survive into the blastocyst of pigs and cattle have been tested and gave very 
preliminary but promising results [82]. Obviously, more studies are needed to 
set up the experimental conditions that are proper to the scope of generating 
xeno-kidneys suitable for kidney replacement purposes. 
Important ethical issues regarding the manipulation of blastocysts and the 
generation of viable humans-animals chimaera mark this strategy. Moreover, 
the experiments are technically difficult to perform and few laboratories have 
the resources necessary to pursue them. As a matter of fact, xeno-generated 
organs need to be extremely “pure” to avoid immune system rejection after 
transplantation, thus raising important questions about how to technically 
obtain “pure” organs of interest after generating the chimeric animals. Finally, 
blastocyst complementation in some organs could be incompatible with life. 
Therefore, besides a very theoretical interest, this strategy, although promising, 





3.2 Understanding kidney regeneration trough modeling of renal diseases 
 
3.2.1 Modeling of renal diseases using pluripotent stem cells 
 
One of the main opportunities of human pluripotent SCs is the development of 
“disease in a dish”, that is to say laboratory models of human kidney diseases, 
that can be used to understand the mechanisms of diseases (Figure 1). They 
represent an important complement to mouse models, which may not fully 
recapitulate human genotypes and phenotypes and are technically and 
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economically costly to generate. ESCs and iPSCs carrying mutations in genes 
responsible for inherited kidney diseases have now been generated (e.g. 
autosomal dominant and recessive polycystic kidney disease, Alport syndrome) 
[10]. 
iPSCs can be obtained from patients with kidney diseases. Harboring mutations 
clearly responsible for the disease, patients-specific iPSCs do not require genome 
editing to recapitulate the pathophysiology of the disease. To this aim, a 
multitude of iPSCs cell cultures have already been obtained and can be used to 
compare in vitro properties with clinical features of patients [10]. As an example, 
they have been extensively used in assessing the process of cystogenesis in 
autosomal dominant polycystic kidney disease (ADPKD) and the role of 
policistin-2 mistrafficking in the cilium in the pathogenesis of the disease [44]. 
These studies demonstrated that the cystic phenotype is less than 100% 
penetrant even in presence of truncating mutations [10]. 
Moreover, some of these mutations could be specie-specific and these cell 
cultures hold not only the mutation of interest but also other variants that could 
eventually act as modifiers. Therefore, the use of iPSCs permits to skip at least 
some issue related to the reproducibility of data obtained from animal models, 
including mice, making them highly indicated in genotype-phenotype 
correlation studies following whole-exome sequencing population screening 
[83]. 
In addition, human iPSCs can be used for drug discovery. Being at the same 
time specie-specific and phenotypically diverse, cell culture obtained from 
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iPSCs are amenable tools to test the effects of new compounds and to evaluate 
efficacy, toxicity and pleiotropic effects [10, 83]. For all these purpose, the 
limiting step seems to be the development of reliable in vitro assays to test the 
feature of interest. 
Finally, human pluripotent SCs can serve as tools to identify new biomarkers for 
renal disorder or to validate existing ones. Their role is quite consolidated  in 
other organs and tissues (e.g. heart, central nervous system, liver) [10]. In   the 
nephrology field, this approach would be of particular interest for AKI. Indeed, 
the identification of up-/down-regulation of specific gene/molecules in 
response to AKI would be of benefit in the early identification of AKI and in the 
preclinical evaluation of drugs/molecules to treat patients, to avoid 
nephrotoxicity and to promote tubular regeneration. In addition, the assessment 
of specific phenotypic features in cell cultures obtained from pluripotent SCs 
carrying mutations in genes responsible for inherited kidney diseases could also 
be considered as biomarkers. As an example, cysts development in cell cultures 
obtained from iPSCs could predict the pathogenicity of genetic variants in 
ADPKD and the development of the phenotype before the clinical onset of the 
disease, acting as a biomarker for disease progression and, potentially, for 
disease severity and prognosis assessment [10]. This could conceptually be 
useful also for other renal disorder, such as nephrotic syndrome and focal 
segmental glomerulosclerosis [10]. 
 
 
3.2.2 Gene editing for kidney regeneration 
23	 
Recent years have seen a significant increase in genome editing techniques 
applied to human cells. Indeed, genome editing provides the possibility to 
efficiently introduce a variety of genetic alterations to the cell of interest, ranging 
from single-nucleotide modification to whole gene addiction or deletion, all 
with high degree of target specificity. Irrespective of the specific genome editing 
strategy used (Zinc-finger Nucleases (ZFN), Transcription activator-like effector 
nucleases (TALEN) and CRISPR-Cas9) these techniques can be applied to 
human pluripotent SCs and permit to correct the disease- causing gene 
mutations if applied to patient-derived iPSCs or to introduce specific mutations 
into non-disease affected wild-type iPSCs (Figure 1) [81]. 
Recently the CRISPR-Cas9 technology has attracted much attention and gained 
wide usage in gene editing both in ESCs and in iPSCs owing to its simplicity in 
design and ease of use. However, a major challenge in the application of this 
technology is the possibility of off-target effects [86]. For this reason, this 
technologies needs to be continuously improved. 
Gene editing of human pluripotent SCs has three principle possible applications: 
1. Elucidating gene function. The cells that have undergone genome editing 
should contain only the intended change in an otherwise isogenic background, 
thus providing the most stringent test of gene function. Freedman et al. [87] 
produced kidney organoids from human pluripotent SCs knocked out for 
podocalyxin by CRISPR-Cas9 in order to investigate its role during kidney 
organogenesis. Comparing the results obtained with wild-type organoids, the 
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authors concluded that podocalyxin is essential for organoid differentiation, 
with particular attention to podocyte junctional organization. 
2. Modeling human diseases. Patient-derived iPSCs are widely used to 
modeling monogenic disorder because they are derived from the patient, easily 
manipulated, clonally expanded and differentiated toward the cells of interest. 
The application of gene editing allows creating isogenic controls with the rescue 
of disease causative gene mutations, avoiding the confusion with genetic 
background or epiphenomena resulting from possible line-to-line variations. 
Recently, to better recapitulate disease phenotypes, human iPSC- derived 3D 
organoids have been developed to study the cell-cell interaction in a cellular 
context that mimics human physiology [88, 89]. In particular an in vitro organoid 
model for ADPKD was performed applying CRiSPR-Cas9 genome editing 
system to introduce biallelic truncating mutations in PKD1 or PKD2 in human 
pluripotent SCs, providing a good and promising approach to model 
cystogenesis [87]. Furthermore, patient-derived iPSCs in addition to enabling 
personalized diseases modeling could be used as potential high- throughput 
drug-screening platforms. 
3. Gene therapy. Ideally, gene editing would lead in the future to new cell 
therapy strategies for the treatment of renal diseases, either by promoting the 
application of non-immunogenic patient’s own iPSCs genetically corrected 
target mutations for kidney repair and regeneration, either by generating 
sources for organ replacement therapy, combining genetically corrected human 
iPSC platform with 3D organoids. In addition, gene editing could also allow 
allogenic iPSCs to be considered from cell therapy from unmatched 
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donor. Moreover, it is also possible that gene editing might also enable to 
generate a “universal donors”, that is to say human pluripotent SCs with 









The kidney is a complex organ. This complexity includes the existence of distinct 
functional compartments, distinct segments within each compartment and 
distinct cell types within each segment. Moreover, a well-defined three- 
dimensional structure involving the correct interaction between renal resident 
cells, vasculature and interstitium is crucial for the proper assumption of the 
functional features. As a consequence, this complexity influences the 
regenerative properties of the tissue. Indeed, in contrast to many other organs 
the diversity of cell types of the kidney requires an extensive variety of 
differentiated cells to be generated in order to ameliorate disease or injury. 
Understanding the mechanisms of endogenous kidney regeneration and repair 
represents another important goal of regenerative nephrology. In other organs, 
the discovery of endogenous stem/progenitors systems fueled identification of 
innovative treatment strategies up to regenerative medicine and tissue 
engineering [90, 91]. In the kidney, the identification of endogenous 
stem/progenitor systems remained a challenge until very recently. 
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As previously stated, mammals are not capable of neo-nephrogenesis. Anyway, 
the existence of kidney regeneration is suggested by clinical and experimental 
evidence [92]. In recent years, conclusive evidence for the existence of renal 
progenitors has been reported in lower vertebrates such as fish, insects and in 
mammals [92-94]. Because of their limited differentiation potential these cells 
have been referred to as renal progenitor cells (RPC). 
In humans, CD133+CD24+ renal epithelial cells have been demonstrated to 
represent a hierarchical population of RPC, containing parietal epithelial cells 
and a scattered population of tubular epithelial cells, that represent about 2-4% 
of total renal cells [92, 95]. They are marked by the co-expression of the cell 
surface markers CD133 and CD24 that permit to recover them from tissue and 
to be grown in culture, so that their functional properties can be assessed in vitro. 
These cells have been shown to possess self-renewal potential, resistance to 
senescence, ability to grow in culture as spheres and the capability to 
differentiate in vitro into several types of renal epithelial cell, such as podocytes 
and tubular epithelial cells, as well as into adipocytes, osteoblasts, endothelial 
cells and neuronal cells [68, 95]. These observations lead to the conclusion that 
CD133+CD24+ renal epithelial cells may represent a multipotent stem cell 
population. The recent observations that amgiomyolipomas in tuberous 
sclerosis derive from a multipotent cancer stem cell that originate from renal 
epithelium confirmed the hypothesis that the renal epithelium may have 
differentiation capacity that goes beyond the epithelial phenotype, which was 
considered to be its only possible lineage based on lineage-tracing experiments 
performed in mouse models of AKI [96-98]. Consistently, CD133+CD24+ renal 
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epithelial cells exhibit cellular plasticity and stem-like properties, such as 
multipotency [92, 95]. Their behavior, such as the differentiation toward 
epithelial cells instead of adipocytes or endothelial cells, is probably influenced 
by niche-specific factors that could profoundly differ in healthy or disease (e.g. 
tumor) microenvironment, as well as in in vitro assays or in transplantation 
experiments [96]. 
Unlike iPSCs, RPC are not generated by the forced expression of SCs genes, but 
can instead be directly isolated from adult human kidneys. Therefore, they are 
frequently referred to as “endogenous SCs”, and can represent further possible 
tools or target for alternative treatment for kidney regeneration. 
 
 




The injection of RPCs into immunopermissive hosts could represent an interesting 
strategy for kidney regeneration. 
Several independent studies demonstrated that adult renal progenitors had therapeutic 
effects in immunodeficient mice with rhabdomyolysis-induced AKI [16, 95, 99-102]. In 
all these models, cell therapy improved measurable renal function and structural injury. 
Afterwards, the administration of CD133+CD24+ cells isolated from the Bowman’s 
capsule improved renal outcomes in a model of FSGS that is characterized by podocyte 
injury [68]. CD133+CD24+ cells that were isolated from urine also differentiated into 
podocytes and reduced proteinuria in mice with adriamycin-induced nephropathy [103]. 
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Multiple studies have demonstrated the therapeutic potential of RPCs isolated from fetal 
kidneys in acute and chronic renal injury. In mice with glycerol-induced AKI, injection 
of human fetal CD133+CD24+ RPCs improved renal function comparably to adult RPCs 
[104]. In the 5/6 nephrectomy model of kidney injury, human fetal nephron NCAM-1+ 
progenitors injected directly into the renal parenchyma engrafted and integrated, with 
consequent improvement of renal function and slowing of disease progression [105]. In 
one study, the therapeutic effects of NCAM-1+ nephron progenitor cells and of cultured 
human CD133+CD24+ renal progenitors in a mouse model of glycerol-induced AKI were 
comparable [106]. 
The exact mechanisms by which human RPCs exert beneficial effects when used for cell 
therapy are not completely elucidated, probably including both paracrine stimulation of 
adjacent cells and tissue integration, even with different persistence in each model [68, 
95, 102, 107]. 
Although potentially promising, the use of renal progenitors for cell therapy of kidney 
injury has also several drawbacks. Sources of RPCs are limited, and tissue from which 
autologous RPCs can be obtained is poorly accessible or insufficient for cell isolation. 
However, it is possible to retrieve autologous RPC from the patient’s urine, a technology 
potentially offering an autologous CKD therapy that should not require 
immunosuppression [103]. 
Outcomes of cell therapy might also depend on the modality of cell delivery to the 
injured compartment. Cells that are delivered intravenously or intra-arterially may 
become trapped in other organs, although this does not seem to happen for RPC [68]. 
Intraparenchymal delivery has the advantages of requiring few cells and avoiding cell 
dispersion in off-target organs, but might be associated with adverse events, such as local 
necrosis, thrombosis and a limited distribution of the cells within the kidney. 
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Finally, it is possible that either the disease process itself or external factors (e.g. drugs) 
may influence the ability of cells to regenerate injured kidneys [71, 108]. Therefore, the 
exact effects of this possibly confounding factors needs to be clearly identified, allowing 
us to enhance the therapeutic potential of these therapies. 
Although the possibility to generate new functional renal tissue by cell therapy 
represents one of the main goals of regenerative nephrology, there is a great lack of 
knowledge about the differentiation processes and how to control them in order to allow 
injected cells to be functional. Indeed, the possible application of cell therapy could not 
still be envisaged until strictly controlled differentiation protocols are developed and 
many molecular mechanisms are understood. 
 
 




The choice of a validated tool of investigation represent a major challenge to understand 
kidney regeneration and find new drugs for modulating it. RPCs can be easily amplified, 
maintained in culture and induced to differentiate into all epithelial cell subtype. 
Therefore they represent an efficient and innovative tool to this purpose (Figure 2). 
Cultures of RPCs can be obtained from human healthy tissues using immunomagnetic 
sorting for CD133 and CD24 (Figure 2) [68, 95, 104]; in addition, the expression of 
CD106 allows us to specifically separate tubular-committed or podocyte-committed 
progenitors [99]. Several studies documented the involvement of dysregulated 
proliferation and migration of RPC at different stages of their differentiation toward 
mature podocytes in the generation of glomerular hyperplastic lesions, highlighting that 
RPC regenerative capacity after injury must be strictly regulated in order to 
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prevent an inefficient or excessive response that can determine a failure in replacing the 
loss podocytes [109, 110]. Therefore, RPC can be used as a useful tool to study the 
pathophysiology of kidney diseases and mechanisms of repair and regeneration. 
However, the inaccessibility of the human RPCs from the affected patients obstacles 
their application for personalized diseases modeling and drug screening in the context of 
the individual's overall genetic and epigenetic background. Recently Lazzeri et al. 
[103] developed a method to isolate and amplify RPCs from renal cells that naturally are 
loss in the urine of patient with renal disorders. In particular, urine-derived RPCs display 
an identical phenotype and functional properties to tissue-derived RPCs  (Figure 2). 
Indeed, the isolation of urine-derived RPC from patients affected by genetic kidney 
disease would be a valuable instrument to achieve a proper functional study aimed to 
clarify the role of the identified variant in the pathophysiology of the disease [103]. 
Moreover, the advent of high-throughput techniques of sequencing has amplified the 
identification of variants of unknown clinical significance and the need of appropriate 
test to establish their pathogenicity [111]. Patient-specific RPCs may be also usefully for 
testing patient-specific safety and efficacy of drugs. Moreover, RPCs can be isolated also 
from the urine of pre-term neonates [112]. These cells show high differentiation ability, 














At different with other pluripotent stem cell populations, RPC have the advantage to 
represent also possible targets to boost kidney regeneration (Figure 2). Indeed, recent 
studies demonstrated that the RPC-mediated kidney regeneration can be modulated 
through many molecules, such as the chemokine SDF-1 blockers [113], Notch signaling 
inhibitors [70], the glycogen synthase kinases 3-α and -β (GSK3s) inhibitor BIO [69], 
retinoic acid [71], as well through several drugs as Interferon [114], Steroids [115], 
renin-angiotensin-aldosterone system inhibitors [116] and Leptin [117]. All these 
pharmacological agents can enhance renal progenitor differentiation into podocytes 
favoring glomerular regeneration or block RPC hyperactivation. 
In particular the beneficial effects of SDF-1blockers, Notch signaling inhibitors and 
renin-angiotensin-aldosterone system inhibitors are attributable to the reduction of 
abnormal RPC proliferation [70, 112, 116], whereas the beneficial effects of the 
glycogen synthase kinases 3-α and -β (GSK3s) inhibitor BIO, retinoic acid, Interferon, 
Steroids and Leptin are attributable to the enhance RPC differentiation into podocytes 
[69, 71, 114-116]. Finally, very recently Lazzeri et al. [118] demonstrated that the 
treatment of mice with HDAC (Histone deacetylases) inhibitors following AKI stimulate 
the proliferation of RPC enhancing the recovery of renal function and a better 










Understanding the molecular and cellular mechanisms of kidney regeneration is 
important for the development of new therapeutic strategies aimed at reversal and/or 
attenuation of kidney damage. Ideally, this should support attempts to therapeutically 
enhance kidney regeneration in order to prevent irreversible nephron loss and CKD. The 
realization of miniaturized organ-on-chip devices, which combine biological and 






6. Expert Opinion 
 
Human pluripotent SCs represent indisputable tools to improve our knowledge. 
Nevertheless, the use of these cells still presents some issues and limitations: 
1. Efficiency: efficient protocols for renal lineage-specific differentiation of 
pluripotent SCs and progenitors usually recapitulate embryonic development 
stages by a step-wise generation of progenitors (from intermediate mesoderm to 
metanephric mesenchyme). It is possible that one of the main limitations in the 
generation of functional kidneys from pluripotent SCs is an incomplete 
definition of the kidney cell lineage specification programs, both in vivo and in 
vitro. This can only be overcome by the definition of robust protocols to generate 
nephrogenic cells. 
2. Similarly, the lack of clearly defined indicators of success in obtaining 
pluripotent stem cell and in their differentiation is troubling. Moreover, 
molecular and morphological phenotyping has not been exhaustive and 
functionality has rarely been analyzed. 
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3. Safety: oncogenic transformation risk must be clearly assessed. Indeed, patient- 
derived iPSCs are expected to be fully immunocompatible with the patient they 
have been obtained from. Therefore, every cells derived from iPSCs is invisible 
to the host immune system and this could theoretically rise questions about the 
potential neoplastic risk evolution; negative effects on nephrogenesis and renal 
growth or kidney injury (by the release of unidentified molecules) should also be 
assessed. 
4. Comparisons: Many studies performed on human pluripotent SCs demonstrated 
that ESCs and iPSCs while essentially similar, exhibit significant variability in 
terms of gene expression profiles and epigenetic factors. These differences can 
be attributed either to the cell lines them-selves, either to laboratory and 
cultures condition. Either way, they influence the differentiation ability of the 
cells and make comparisons between cells in disease modeling not fully reliable. 
5. Reliability in disease modeling: kidney diseases are complex and the 
pathophysiology of the progression is probably influenced by multiple factor 
related not only to kidney but also to other organs and functions. In vitro cell 
cultures have the intrinsic limit of not reproducing this complexity and can 
probably provide information only at a cellular and molecular level. 
 
 
All these issues underline the need of a deeper knowledge of the biology of 
pluripotent SCs, in order to shorten the distance that separate their use from 
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Figure 1. Schematic representation of the possible applications of human 
pluripotent stem cells to kidney regeneration. 
Once human pluripotent stem cells have been obtained from patients (iPSCs) or from 
blastocyst (ESCs), they can be cultured in vitro and induced to differentiation into the 
cell type of interest. Afterwards, these cells can be used to generate organoids, to 
repopulate scaffolds or to generate biological microdevices or for blastocyst 
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complementation. In addition, cell cultures derived from human pluripotent stem cells 
can be used for kidney diseases modeling (e.g. drug screening, gene editing). 
 
 





Figure 2. Schematic representation of the possible applications of  renal progenitor 
cells cells to kidney regeneration. 
Renal progenitor cells can be obtained from kidney tissue or from fresh urine samples. 
Renal progenitor cells can be cultured in vitro and induced to differentiate into the cell 
type of interest. Afterwards, these cell cultures can be used for understanding the 
pathophysiology of kidney regeneration and to unravel potential mechanisms to enhance 
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